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Objectives: To investigate the differences of clinical
features, cerebrospinal fluid (CSF), MRI findings and
response to steroid therapies between patients with
optic neuritis (ON) who have myelin oligodendrocyte
glycoprotein (MOG) antibodies and those who have
seronegative ON.
Setting: We recruited participants in the department of
neurology and ophthalmology in our hospital in Japan.
Methods: We retrospectively evaluated the clinical
features and response to steroid therapies of patients
with ON. Sera from patients were tested for antibodies to
MOG and aquaporin-4 (AQP4) with a cell-based assay.
Participants: Between April 2009 and March 2014, we
enrolled serial 57 patients with ON (27 males, 30
females; age range 16–84 years) who ophthalmologists
had diagnosed as having or suspected to have ON with
acute visual impairment and declined critical flicker
frequency, abnormal findings of brain MRI, optical
coherence tomography and fluorescein fundus
angiography at their onset or recurrence. We excluded
those patients who fulfilled the diagnostic criteria of
neuromyelitis optica (NMO)/NMO spectrum disorders
(NMOSD), MS McDonald’s criteria, and so on. Finally we
defined 29 patients with idiopathic ON (14 males, 15
females, age range 16–84 years).
Results: 27.6% (8/29) were positive for MOG antibodies
and 3.4% (1/29) were positive for AQP4. Among the eight
patients with MOG antibodies, five had optic pain
(p=0.001) and three had prodromal infection (p=0.179).
Three of the eight MOG-positive patients showed
significantly high CSF levels of myelin basic protein
(p=0.021) and none were positive for oligoclonal band in
CSF. On MRIs, seven MOG-positive patients showed high
signal intensity on optic nerve, three had a cerebral lesion
and one had a spinal cord lesion. Seven of the eight MOG-
positive patients had a good response to steroid therapy.
Conclusions: Although not proving primary
pathogenicity of anti-MOG antibodies, the present results
indicate that the measurement of MOG antibodies is useful
in diagnosing and treating ON.
INTRODUCTION
Myelin oligodendrocyte glycoprotein (MOG) is
detected mainly at the extracellular surface of
myelin sheaths and oligodendrocytes in the
central nervous system,1 and autoantibodies
against MOG are found in patients with paedi-
atric multiple sclerosis (MS), acute dissemi-
nated encephalomyelitis, and neuromyelitis
optica (NMO).2–5 In 2013, a study by Sato et al6
that included MOG antibody-positive patients
among their patients with NMO spectrum dis-
orders (NMOSD), described optic neuritis
(ON) or longitudinally extensive transverse
myelitis (LETM) with three or more vertebral
segment spinal cord lesions observed on MRI.
Sato et al6 also reported that males predomi-
nated (0.6:1.0) in the patients with MOG anti-
bodies. Tanaka and Tanaka7 reported that 75%
of MOG antibody-positive patients (three of
four patients who were also negative for
aquaporin-4 (AQP4) antibodies) had optic
nerve lesions, and Kezuka et al8 showed a rela-
tionship between NMO antibody and MOG
antibody in ON and visual outcomes. Some
recent case reports also showed ON with serum
MOG antibodies,8 but there are no detailed
reviewed data for idiopathic ON that include
the epidemiology, prodromal infection, serum
and cerebrospinal fluid (CSF) examination,
and MRI findings.
In the present study, we reviewed some
new findings regarding idiopathic ON with
and without MOG antibodies, by examining
a series of patients with ON at the acute
Strengths and limitations of this study
▪ This cohort illuminates the characteristics of
autoimmune optic neuritis (ON) with antibodies
against myelin oligodendrocyte glycoprotein
(MOG).
▪ Of 29 patients with idiopathic ON, 27.6% were
positive for MOG antibodies.
▪ The measurement of MOG antibodies by cell-
based assay was useful in diagnosing auto-
immune ON.
▪ The patients with MOG-positive ON had a good
response to steroid therapy.
▪ A limitation of this study was that the sample
size was small, so a prospective multicentre
study is needed.
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Between April 2009 and March 2014, we enrolled serial 57
patients with ON (27 males, 30 females; age range 16–84
years) who ophthalmologists had diagnosed as having or
suspected to have ON with acute visual impairment and
declined critical flicker frequency, abnormal findings of
brain MRI, optical coherence tomography and fluorescein
fundus angiography at their onset or recurrence at
Nagasaki University Hospital, Japan. We excluded the
patients who fulfilled the diagnostic criteria of NMO/
NMOSD,9 MS McDonald’s criteria,10 ischaemic optic neu-
ropathies, orbital apex syndromes, Leber’s hereditary
optic neuropathies, tumours, trauma, thyroid-associated
ophthalmopathy, pentazocine and alcohol-induced,
Tolosa-Hunt syndrome, dissociated disorder and
IgG4-related disease. Finally, we defined 29 patients with
idiopathic ON as the study cohort (figure 1), and we retro-
spectively reviewed their clinical symptoms and results of
their CSF examination, MRI studies and response to
steroid therapies. We used ELISA for myelin basic protein
(MBP) analysis, of which the cut-off level was 102 pg/mL.
We prepared a standard protocol of steroid pulse therapy:
methylprednisolone (mPSL) 1 g/day for three consecutive
days per week for 1–5 weeks. We defined the terms to
evaluate the responsiveness to steroid pulse therapies in
the acute phase (before other treatments; eg, plasma
exchange, fingolimod); ‘complete’ meant recovery to the
patients’ original visual acuities, ‘good’ meant recovery to
more than half of their original visual acuities, ‘not good’
meant less than ‘good’ within 1–5 courses of mPSL pulse
therapies. All of the sera samples were obtained from the
patients in an acute phase at their onset or recurrence.
The range of follow-up period was 3–53 months (see
online supplementary table).
Antibody assays
We transfected a full-length human MOG cDNA expres-
sion vector (kindly gifted by Prof Markus Reindl) into 293
cells of human embryonic kidney (HEK) using
Lipofectamine reagent (Invitrogen Japan, Tokyo, Japan).
Cell cultures were maintained in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal calf serum.
Twelve hours after transfection, the HEK cells were fixed
in 4% paraformaldehyde in 0.1 M phosphate-buffered
saline (PBS) for 20 min. Non-specific binding was blocked
with 10% goat serum/PBS; the cells were incubated with
patient sera (dilution, 1:10) in 0.02% Triton X-100/10%
goat serum in PBS for 1 h at room temperature followed
by fluorescein isocyanate-conjugated antihuman IgG (dilu-
tion 1:50; DAKO Denmark, Glostrup, Denmark) for 1 h.
SlowFade Gold antifade reagent (Invitrogen, Carlsbad,
California, USA) was then applied to the slides, which
were stained and observed using a fluorescence micro-
scope (AxioVision, Carl Zeiss Microscopy, Germany).
Serum anti-AQP4 IgG antibody levels were analysed
using a previously reported indirect immunofluores-
cence assay of HEK-293 cells transfected with an expres-
sion vector containing human AQP4 M23 cDNA.7 The
examiner (KT) of the anti-MOG and anti-AQP4 anti-
bodies was blinded to all clinical data, including the clin-
ical phenotype.7
Statistical analysis
We analysed the differences in categorical data between
the group of patients with ON with MOG antibodies
and the seronegative ON group using the Microsoft




Of the 57 serial ON or suspected patients with ON, we
excluded other demyelinating disorders (see figure 1)
and enrolled 29 patients with idiopathic ON (14 males,
15 female, age range 16–84 years). Eight (two male, six
female) of the 29 patients with ON (27.6%) were posi-
tive for MOG antibodies, and one patient was double-
positive for MOG and AQP4 (table 1).
Demographic and clinical data
The median age of the eight MOG antibody-positive
patients was 31 years, which is marginally younger
than that of the patients with ON without MOG anti-
bodies, 51 years (p=0.052). Five of the eight patients had
optic pain (p=0.001), three had prodromal infection
Figure 1 Patient enrolment flow chart. Ophthalmologists
diagnosed ON with the disturbance of optic acuity, visual field,
critical flicker frequency (CFF), brain MRI, optical coherence
tomography (OCT) and fluorescein fundus angiography. ION,
ischaemic optic neuropathy; LHON, Leber’s hereditary optic
neuropathy; MS, multiple sclerosis; NMO, neuromyelitis
optica; NMOSD, neuromyelitis optica spectrum disorders;
OAS, orbital apex syndrome; ON, optic neuritis; TAO,
thyroid-associated ophthalmopathy; THS, Tolosa-Hunt
syndrome; MOG, myelin oligodendrocyte glycoprotein.
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(p=0.179, table 1) and two had bilateral ON (see online
supplementary table).
Two of the eight patients with MOG antibodies (25.0%)
were positive for antinucleotide antibodies, compared to
only three of the 18 seronegative patients with ON (16.6%).
One patient had thyroid peroxidase antibodies, one had
thyroid-stimulating hormone receptor antibodies and one
had glomerular basement membrane antibodies; all had no
neurological symptoms except for ON. All eight of the
MOG antibody-positive patients were negative for oligoclo-
nal band (OCB) in CSF, and only one seronegative ON
patient was positive (5.5%, 1/18). In addition, 37.5% (3/8)
of the patients with ON with MOG antibodies indicated sig-
nificant positivity for MBP in CSF, as did 5.5% (1/18) of the
seronegative patients with ON (p=0.021, table 1). The CSF
cell count was not significantly different between the
MOG-positive and MOG-negative ON groups (p=0.179).
Seven of the eight patients with ON with MOG anti-
bodies without active underlying disease showed com-
plete response to steroid pulse therapy. Although only
one ON patient (patient 4, online supplementary table)
with MOG antibodies emerged with myelitis at her
third recurrence after 12 months from onset and had
received plasma exchange, no one in the seronegative
ON group exhibited myelitis (p=0.106). After her third
recurrence, we prescribed fingolimod according to MS
therapy, but she suffered from left optic pain and visual
disturbance 19 days later, and thus we immediately
stopped the fingolimod treatment. The single patient
with AQP4 and MOG antibodies, who had gastric
cancer, showed complete response following steroid
therapy, in comparison to a previous report.8 The
median follow-up period for patients with MOG anti-
bodies was 26.5 months (range 3–53 months), 23 months
(range 3–53 months) for monophasic patients and
30 months (range 22–52 months) for relapsed patients
(see online supplementary table).
MRI
All 29 idiopathic patients with ON had undergone a brain
and/or spinal MRI in their acute phase. We focused on
three lesions (optic nerve, cerebrum and spinal cord) and
evaluated the abnormal intensities between the patients
with ON with MOG antibodies and those without MOG
antibodies. We found that 66.7% (14/21) of the patients
without MOG antibodies showed high intensities on
T2-weighted images (T2WI) in their optic nerves, as did
87.5% (7/8) of the MOG-positive patients (p=0.278). We
detected high intensities in the cerebrum of 33.3% (7/21)
of the MOG-negative patients and in 25.0% (2/8) of the
Table 1 Comparison of clinical features, antibodies and CSF data, MRI findings and outcome of steroid therapy in idiopathic ON
MOG antibodies
Negative (n=21) Positive (n=8) p Value
Total 21 (72.4%) 8 (27.6%) –
Male:female 12:9 2:6 0.130
Age
Range 22–84 16–65 –
Median 51.0 31.0 0.052
Prodromic infection 3 (14.3%) 3 (37.5%) 0.179
Underlying disease
Diabetes mellitus 4 (19.0%) 1 (12.5%) 0.689
Autoimmune disorders 2 (9.5%) 1 (12.5%) 0.821
Malignancy 4 (19.0%) 2 (25.0%) 0.734
Symptoms
Visual disturbance 21 (100%) 8 (100%) –
Optic pain 2 (9.5%) 5 (62.5%) 0.001
Serum AQP4 antibodies 0 (0%) 1 (12.5%) 0.106
CSF examination
Pleocytosis (>5/μL) 3 (14.3%) 3 (37.5%) 0.179
MBP high level (>102 pg/mL) 0 (0%) 3 (37.5%) 0.021
Oligoclonal band 1 (5.2%) (n=19) 0 (0%) 0.527
Abnormal intensity on MRI
Optic nerve 14 (66.7%) 7 (87.5%) 0.278
Cerebrum 7 (33.3%) 2 (25.0%) 0.840
Spinal cord 0 (0%) 1 (12.5%) 0.106
Therapies in acute phase
Steroid pulse 17 (80.9%) 8 (100%) 0.196
Oral prednisolone 3 (14.2%) 0 (0%) 0.262
Plasma exchange 0 (0%) 1 (12.5%) 0.106
Good or complete response to steroid therapy: 17 (81.0%) 7 (87.5%) 0.870
Recurrence 3 (14.3%) 2 (25.0%) 0.512
Oral prednisolone; 20 mg/day.
AQP4, aquaporin-4; CSF, cerebrospinal fluid; MBP, myelin basic protein; MOG, myelin oligodendrocyte glycoprotein; ON, optic neuritis.
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MOG-positive patients (p=0.840), and high intensities in
the spinal cord in 0% (0/8) and 12.5% (1/8) of these
patients, respectively (p=0.106). Regarding patient 4, T2WI
on spinal MRI showed high signal on the vertebral level of
Th11 and Th12 segmentally and did not show LETM.
DISCUSSION
We have reported the detailed clinical features of serial
patients with ON with MOG antibodies. Similar to previ-
ous reports, we observed that the patients with ON with
MOG antibodies were marginally younger than those
without MOG antibodies, as in other autoimmune dis-
eases (p=0.052). Optic pain was a significant symptom
for our MOG-positive idiopathic patients with ON
(p=0.001). Unlike MS, no ON patient with MOG anti-
bodies showed positivity for CSF OCB. In addition, our
patients with ON with MOG antibodies showed signifi-
cantly high levels of CSF MBP compared to those of the
seronegative patients with ON (p=0.021).
Myelitis was not frequently observed among the present
idiopathic patients with ON with MOG antibodies, com-
pared to a previous report.11 We suspect that the optic
nerve is sensitive to MOG antibodies and that MOG anti-
bodies cause demyelination by some immunological
mechanisms, resulting in swelling and optic pain; steroid
therapies might thus be effective. In the present series of
patients, the swelling and high signals on MRI T2WI of
optic nerves were decreased after steroid therapy. The
patient with gastric cancer who was double-positive for
AQP4 and MOG antibodies achieved a complete
response to steroid therapy, but another patient (patient
6, online supplementary table) who had autoimmune
disease, showed no response to steroid therapy, as
described previously.8 12 Except for the above patient, the
optic pain and visual acuity of our MOG-positive patients
improved completely, but there was no significant differ-
ence in the clinical outcomes at the end of steroid pulse
therapies between the patients with idiopathic ON with
MOG antibodies and those without MOG antibodies
(p=0.870). When selecting a drug for the prevention of
ON recurrence, we should deliberate and choose it based
on neurological symptoms, the results of serum AQP and
MOG antibody tests, and the CSF MBP level. It is possible
that some immunosuppressants induce a recurrence of
idiopathic ON with MOG antibodies.
CONCLUSIONS
MOG is considered a target antigen in some demyelinat-
ing disorders, and MOG antibodies cause demyelination
and ON,13 similar to the pathogenesis of MS.14 When
clinicians encounter a patient with idiopathic ON, the
patient’s CSF, MRI, serum AQP4 antibodies and MOG
antibodies, might be useful to diagnose and treat.
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